ASCP SMB Exam Prep: PGx-QUESTIONS &
ANSWERS VERIFIED 100% CORRECT
Pharmacokinetics
what the body does to the drug
Pharmcodynamics
what the drug does to the body
Pharmacologic phenotypes associated with metabolism:
Ultra Metabolizer
Rapid (Normal) Metabolizer
Intermediate Metabolizer
Poor Metabolizer
Area under the curve (AUC)
- The average amount of a particular drug in the blood after a dose is given. It is a measure of the
availability (bioavailability) of a drug after it is administered.
Genetic variants in drug metabolizing enzyme genes may decrease enzyme function. This
would result in ___ clearance, ___ AUC, ___ half life.
decreased, increased, increased
Genetic variants in drug metabolizing enzyme genes may increase enzyme function. This
would result in ___ clearance, ___ AUC, ___ half life.
increased, decreased, decreased
, haplotype
set of closely linked alleles that are located on one chromosome and inherited together as a
unit/block
diplotype
specific combination of two haplotypes
Ultra Metabolizer
phenotypic variation causing rapid drug clearance of parent drug --> decreased efficacy
Rapid (Normal) Metabolizer
lack of phenotypic variation causing normal drug clearance --> normal response
Intermediate Metabolizer
phenotypic variation causing reduced drug clearance of parent drug --> increased efficacy,
intermediate risk of ADRs
Poor Metabolizer
phenotypic variation causing poor drug clearance of parent drug --> increased efficacy, high risk
of ADRs
Clinical Pharmacogenetics Implementation Consortium (CPIC)
an international consortium of individual volunteers and a small, dedicated staff who are
interested in facilitating use of PGx tests for patient care
parent drug
ANSWERS VERIFIED 100% CORRECT
Pharmacokinetics
what the body does to the drug
Pharmcodynamics
what the drug does to the body
Pharmacologic phenotypes associated with metabolism:
Ultra Metabolizer
Rapid (Normal) Metabolizer
Intermediate Metabolizer
Poor Metabolizer
Area under the curve (AUC)
- The average amount of a particular drug in the blood after a dose is given. It is a measure of the
availability (bioavailability) of a drug after it is administered.
Genetic variants in drug metabolizing enzyme genes may decrease enzyme function. This
would result in ___ clearance, ___ AUC, ___ half life.
decreased, increased, increased
Genetic variants in drug metabolizing enzyme genes may increase enzyme function. This
would result in ___ clearance, ___ AUC, ___ half life.
increased, decreased, decreased
, haplotype
set of closely linked alleles that are located on one chromosome and inherited together as a
unit/block
diplotype
specific combination of two haplotypes
Ultra Metabolizer
phenotypic variation causing rapid drug clearance of parent drug --> decreased efficacy
Rapid (Normal) Metabolizer
lack of phenotypic variation causing normal drug clearance --> normal response
Intermediate Metabolizer
phenotypic variation causing reduced drug clearance of parent drug --> increased efficacy,
intermediate risk of ADRs
Poor Metabolizer
phenotypic variation causing poor drug clearance of parent drug --> increased efficacy, high risk
of ADRs
Clinical Pharmacogenetics Implementation Consortium (CPIC)
an international consortium of individual volunteers and a small, dedicated staff who are
interested in facilitating use of PGx tests for patient care
parent drug
